$JRSS
JRSIS HEALTH CARE Corp

2023 Q3 Form 10-Q Financial Statement

#000121390023069101 Filed on August 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q4
Revenue $13.57K $43.32K $89.17K
YoY Change -99.32%
Cost Of Revenue $377.3K $297.8K
YoY Change
Gross Profit $120.1K $39.61K
YoY Change
Gross Profit Margin 885.3% 91.44%
Selling, General & Admin $120.0K $140.0K $127.5K
YoY Change -4.28% 39.5% -96.35%
% of Gross Profit 99.91% 353.44%
Research & Development $36.20K $38.34K
YoY Change
% of Gross Profit 30.14% 96.8%
Depreciation & Amortization $10.00K $0.00 $2.130K
YoY Change 361.68% -100.0% -99.75%
% of Gross Profit 8.33% 0.0%
Operating Expenses $130.0K $150.0K $133.0K
YoY Change -1.86% 17.84% -98.52%
Operating Profit -$119.1K -$105.0K
YoY Change -10.06% -17.51%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$1.740K
YoY Change -100.57%
Pretax Income -$119.1K -$105.0K -$45.56K
YoY Change -10.06% -17.51% -102.97%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$119.1K -$105.0K -$45.56K
YoY Change -10.06% -17.51% -105.24%
Net Earnings / Revenue -878.11% -242.41% -51.09%
Basic Earnings Per Share -$0.02 -$0.02
Diluted Earnings Per Share -$0.02 -$0.02 $0.00
COMMON SHARES
Basic Shares Outstanding 5.837M shares 58.37M shares 58.37M shares
Diluted Shares Outstanding 5.837M shares 5.837M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.00K $30.00K $58.62K
YoY Change 170.76% -20.34% -93.15%
Cash & Equivalents $33.39K $28.22K $58.62K
Short-Term Investments
Other Short-Term Assets $490.0K $570.0K $736.4K
YoY Change -40.11% -36.67% -77.5%
Inventory $562.0K
Prepaid Expenses
Receivables $13.79K
Other Receivables $2.836K $2.841K $2.987K
Total Short-Term Assets $527.2K $617.6K $798.9K
YoY Change -36.67% -35.3% -94.24%
LONG-TERM ASSETS
Property, Plant & Equipment $30.84K $33.05K $38.99K
YoY Change -22.77% -25.76% -99.93%
Goodwill
YoY Change
Intangibles $303.2K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $37.55K $43.78K $57.13K
YoY Change -38.94% -38.76% -99.91%
TOTAL ASSETS
Total Short-Term Assets $527.2K $617.6K $798.9K
Total Long-Term Assets $37.55K $43.78K $57.13K
Total Assets $564.7K $661.4K $856.0K
YoY Change -36.82% -35.54% -98.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.000K $8.000K $24.71K
YoY Change 0.0% 0.0% -99.8%
Accrued Expenses $10.00K $10.00K $18.52K
YoY Change -42.95% -45.56% -99.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $49.71K
YoY Change -97.33%
Total Short-Term Liabilities $90.97K $69.39K $43.23K
YoY Change 230.46% 163.12% -99.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $0.00 $1.430K
YoY Change -100.0% -100.0% -99.97%
Total Long-Term Liabilities $0.00 $0.00 $1.430K
YoY Change -100.0% -100.0% -99.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $90.97K $69.39K $43.23K
Total Long-Term Liabilities $0.00 $0.00 $1.430K
Total Liabilities $90.97K $69.39K $44.66K
YoY Change 175.25% 89.84% -99.92%
SHAREHOLDERS EQUITY
Retained Earnings -$24.05M -$23.93M -$23.71M
YoY Change 1.64% 1.71% 1162.76%
Common Stock $583.00 $583.00 $58.37K
YoY Change -99.0% -99.0% 213.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $473.7K $592.0K $811.3K
YoY Change
Total Liabilities & Shareholders Equity $564.7K $661.4K $856.0K
YoY Change -36.82% -35.54% -98.87%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q4
OPERATING ACTIVITIES
Net Income -$119.1K -$105.0K -$45.56K
YoY Change -10.06% -17.51% -105.24%
Depreciation, Depletion And Amortization $10.00K $0.00 $2.130K
YoY Change 361.68% -100.0% -99.75%
Cash From Operating Activities $10.00K $10.00K $67.33K
YoY Change -98.85% -100.4% -92.12%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$1.730K
YoY Change -100.0% -100.0% -100.15%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00 $1.720K
YoY Change -100.0% -100.0% -99.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities 10.00K 10.00K 67.33K
Cash From Investing Activities 0.000 0.000 1.720K
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash 10.00K 10.00K 69.05K
YoY Change -128.91% -100.67% -73.5%
FREE CASH FLOW
Cash From Operating Activities $10.00K $10.00K $67.33K
Capital Expenditures $0.00 $0.00 -$1.730K
Free Cash Flow $10.00K $10.00K $69.06K
YoY Change -98.85% -100.28% -121.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56013
dei Entity Registrant Name
EntityRegistrantName
JRSIS HEALTH CARE CORPORATION.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4562047
dei Entity Address Address Line1
EntityAddressAddressLine1
3/F Building A
dei Entity Address Address Line2
EntityAddressAddressLine2
De Run YuanNo. 19 Chang Yi Road
dei Entity Address Address Line3
EntityAddressAddressLine3
Chang Ming ShuiWu Gui Shan
dei Entity Address City Or Town
EntityAddressCityOrTown
Zhong Shan City
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
528458
dei City Area Code
CityAreaCode
+86
dei Local Phone Number
LocalPhoneNumber
760-88963658
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5836659 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28220 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58616 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13791 usd
CY2023Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2841 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2987 usd
CY2022Q4 jrss Amount Due From Related Parties
AmountDueFromRelatedParties
854 usd
CY2023Q2 us-gaap Deferred Costs Current
DeferredCostsCurrent
572750 usd
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
736393 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
617602 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
798850 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33051 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38989 usd
CY2023Q2 jrss Rightofuse Assets
RightofuseAssets
10730 usd
CY2022Q4 jrss Rightofuse Assets
RightofuseAssets
18138 usd
CY2023Q2 us-gaap Assets
Assets
661383 usd
CY2022Q4 us-gaap Assets
Assets
855977 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
24711 usd
CY2023Q2 jrss Amount Due To Related Parties
AmountDueToRelatedParties
49491 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1172 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1812 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10730 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16708 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
69393 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
43231 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1430 usd
CY2023Q2 us-gaap Liabilities
Liabilities
69393 usd
CY2022Q4 us-gaap Liabilities
Liabilities
44661 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5836659 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5836659 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5836659 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5836659 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
583 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
583 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24510284 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24510284 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23929915 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23705746 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11038 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3125053 shares
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6195 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
591990 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
811316 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
661383 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
855977 usd
CY2023Q2 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
43317 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
43317 usd
CY2023Q2 us-gaap Revenues
Revenues
43317 usd
us-gaap Revenues
Revenues
43317 usd
CY2023Q2 jrss Rentals And Leases
RentalsAndLeases
3176 usd
CY2022Q2 jrss Rentals And Leases
RentalsAndLeases
4421 usd
jrss Rentals And Leases
RentalsAndLeases
7978 usd
jrss Rentals And Leases
RentalsAndLeases
4421 usd
CY2023Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
81822 usd
CY2022Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
81822 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
163643 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
81822 usd
CY2023Q2 us-gaap Supplies Expense
SuppliesExpense
7221 usd
CY2022Q2 us-gaap Supplies Expense
SuppliesExpense
25430 usd
us-gaap Supplies Expense
SuppliesExpense
10777 usd
us-gaap Supplies Expense
SuppliesExpense
39756 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5441 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5615 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
8196 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5615 usd
CY2023Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
241 usd
CY2022Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
497 usd
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
381 usd
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
497 usd
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
48335 usd
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
8000 usd
us-gaap Professional Fees
ProfessionalFees
72287 usd
us-gaap Professional Fees
ProfessionalFees
16000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7 usd
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2086 usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1505 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4224 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1505 usd
CY2023Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
148322 usd
CY2022Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
127290 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
267486 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
149609 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-105005 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-127290 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-224169 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-149609 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-105005 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-127290 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-224169 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-149609 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-105005 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-127290 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-224169 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-149609 usd
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-36054805 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-33393670 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-105005 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-36182095 usd
us-gaap Net Income Loss
NetIncomeLoss
-224169 usd
us-gaap Net Income Loss
NetIncomeLoss
-33543279 usd
CY2023Q2 jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-5100 usd
CY2022Q2 jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-6356 usd
jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-4843 usd
jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-17557 usd
CY2022Q2 jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
-104913 usd
jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
-301922 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-99905 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-36070826 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-219326 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-33223800 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.018
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.029
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.038
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.048
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.018
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.029
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.038
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.048
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-8.218
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-10.686
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-8.218
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-10.686
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.018
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.247
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.038
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.734
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.018
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.247
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.038
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.734
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5836659 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4387248 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5836659 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3125053 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5836659 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4387248 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5836659 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
33102180 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
2638816 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
208210 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
35949206 usd
CY2022Q2 jrss Loss From Discontinuing Operations
LossFromDiscontinuingOperations
-34984724 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-127290 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
1056510 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
60000 usd
CY2022Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
-970560 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6356 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
989498 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
811316 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-119164 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-257 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
691895 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-105005 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
5100 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
591990 usd
us-gaap Net Income Loss
NetIncomeLoss
-224169 usd
us-gaap Net Income Loss
NetIncomeLoss
-33543279 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-33393670 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-224169 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-149609 usd
us-gaap Depreciation
Depreciation
4224 usd
us-gaap Depreciation
Depreciation
1505 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
8196 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
381 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7 usd
us-gaap Share Based Compensation
ShareBasedCompensation
163643 usd
us-gaap Share Based Compensation
ShareBasedCompensation
81822 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
13791 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-146 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
3219 usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-854 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-16711 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-58000 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
49491 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-640 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-1583 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-28376 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-125925 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
3157978 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28376 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3032053 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
44518 usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-44518 usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-2783041 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2827559 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
69260 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60000 usd
jrss Derivative Financial Instruments
DerivativeFinancialInstruments
7 usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
129267 usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-867508 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-738241 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2020 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-284565 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30396 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-818312 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58616 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
855971 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28220 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37659 usd
CY2023Q2 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
28220 usd
CY2022Q2 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
37659 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28220 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37659 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-13086 usd
us-gaap Interest Paid Discontinued Operations
InterestPaidDiscontinuedOperations
406544 usd
us-gaap Stock Issued1
StockIssued1
163643 usd
us-gaap Stock Issued1
StockIssued1
1056510 usd
jrss Shares Repurchase
SharesRepurchase
-970560 usd
CY2022Q2 jrss Equity Method Investment Ownership Percent
EquityMethodInvestmentOwnershipPercent
0.70 pure
CY2022Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
539200 shares
CY2023Q2 us-gaap Shares Issued
SharesIssued
1 shares
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>C. Use of estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13791 usd
CY2023Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
13791 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>E. Concentration of Credit Risk</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The majority of sales are either cash receipt in advance or cash receipt upon delivery. As of June 30, 2023, one customer accounted for 100% of net accounts receivable, and as of December 31, 2022, no customer accounted for more than 5% of net accounts receivable. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited. For the six months ended June 30, 2023, one customer accounted for 100% of total revenue. For the six months ended June 30, 2022, no customer accounted for more than 10% of net revenue.</p>
jrss Concentration Risk Threshold Percentage
ConcentrationRiskThresholdPercentage
1 pure
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
jrss Negotiated Value
NegotiatedValue
1056510 usd
CY2023Q2 us-gaap Other Additional Capital
OtherAdditionalCapital
74652 usd
us-gaap Other Expenses
OtherExpenses
981858 usd
jrss Expense Term Year
ExpenseTermYear
P3Y
jrss Compensation Expenses
CompensationExpenses
163643 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
5682 usd
us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.25 pure
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>O. Reclassification</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The comparative figures before April 1, 2022 have been reclassified to conform to current year presentation to reflect the disposal of a component of business derived from the recognition of a spin-off transaction on April 28, 2022.</p>
us-gaap Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
0.70 pure
CY2023Q2 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
539200 shares
CY2023Q2 us-gaap Accounts Receivable Gross
AccountsReceivableGross
13791 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
42464 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
44644 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9413 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5655 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33051 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38989 usd
us-gaap Depreciation
Depreciation
4224 usd
us-gaap Depreciation
Depreciation
1505 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1528 usd
CY2023Q2 jrss Net Lease Assets
NetLeaseAssets
10730 usd
CY2023Q2 jrss Net Lease Liabilities
NetLeaseLiabilities
10730 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10730 usd
CY2023Q2 us-gaap Other Assets
OtherAssets
10730 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10730 usd
CY2023Q2 us-gaap Other Liabilities
OtherLiabilities
10730 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
10730 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10730 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
6112 usd
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
8577 usd
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
6122 usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
43317 usd
us-gaap Revenues
Revenues
43317 usd
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.25 pure
CY2022Q2 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
3913000 shares
CY2022Q2 us-gaap Partners Capital Account Units Sold In Private Placement
PartnersCapitalAccountUnitsSoldInPrivatePlacement
800000 shares
CY2022Q2 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
4713000 shares
jrss Negotiated Value
NegotiatedValue
1056510 usd
CY2023Q2 us-gaap Other Additional Capital
OtherAdditionalCapital
74652 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
981858 usd
jrss Compensation Expenses
CompensationExpenses
163643 usd
jrss Compensation Expenses
CompensationExpenses
81822 usd
CY2022Q1 jrss Owned Percentage
OwnedPercentage
1 pure
CY2022Q2 us-gaap Shares Issued
SharesIssued
3913000 shares
CY2022Q2 jrss Acquired Shares
AcquiredShares
800000 shares
CY2022Q2 jrss Owned Shares
OwnedShares
4713000 shares
CY2022Q2 jrss Common Stock Percentage
CommonStockPercentage
0.807 pure
CY2022Q1 jrss Total Share Issued
TotalShareIssued
600000 shares
CY2022Q1 us-gaap Dividends Common Stock Stock
DividendsCommonStockStock
60000 usd
CY2022Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.01
CY2022Q2 jrss Transfer Agreement Description
TransferAgreementDescription
Runteng entered into an agreement regarding a transfer of Jiarun’s equity with Zhang Junsheng. Pursuant to the transfer agreement, Runteng transferred to Mr. Zhang equity interest in Jiarun, representing 70% of equity interest in Jiarun and Mr. Zhang transferred to Runteng 539,200 shares of the Company’s common stock. On May 27, 2022, the Company cancelled the 539,200 shares of the Company’s common stock. Since this transaction required certain authoritative approval before effective, the publication of these transactions was delayed so as to obtain all parties consent and advance authoritative approval. As of May 27, 2022, the issued and outstanding share number of the Company was 5,836,657, the balance of the number of shares held by Mr. Zhang and Mr. Zhong were nil (0%) and 4,713,000 (80.7%), respectively.
CY2023Q2 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
10 shares
CY2023Q2 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
1 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5836659 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5836659 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5836659 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5836659 shares
jrss Substantial Loss
SubstantialLoss
224169 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23929915 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
usd
CY2023Q2 jrss Amount Due From Related Parties
AmountDueFromRelatedParties
usd
CY2022Q4 jrss Amount Due To Related Parties
AmountDueToRelatedParties
usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
usd
us-gaap Revenues
Revenues
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
usd
us-gaap Other Noncash Expense
OtherNoncashExpense
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
jrss Derivative Financial Instruments
DerivativeFinancialInstruments
usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Interest Expense
InterestExpense
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Interest Paid Discontinued Operations
InterestPaidDiscontinuedOperations
usd
jrss Shares Repurchase
SharesRepurchase
usd
CY2022Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
usd
CY2023Q2 jrss Lease Liabilities Noncurrent
LeaseLiabilitiesNoncurrent
usd
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
usd
us-gaap Revenues
Revenues
usd
jrss Expense Term Year
ExpenseTermYear
P3Y
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001597892

Files In Submission

Name View Source Status
jrss-20230630_lab.xml Edgar Link unprocessable
0001213900-23-069101-index-headers.html Edgar Link pending
0001213900-23-069101-index.html Edgar Link pending
0001213900-23-069101.txt Edgar Link pending
0001213900-23-069101-xbrl.zip Edgar Link pending
f10q0623ex31-1_jrsishealth.htm Edgar Link pending
f10q0623ex31-2_jrsishealth.htm Edgar Link pending
f10q0623ex32-1_jrsishealth.htm Edgar Link pending
f10q0623ex32-2_jrsishealth.htm Edgar Link pending
f10q0623_jrsishealth.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
jrss-20230630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
jrss-20230630_def.xml Edgar Link unprocessable
jrss-20230630_cal.xml Edgar Link unprocessable
f10q0623_jrsishealth_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
jrss-20230630_pre.xml Edgar Link unprocessable